PML7789 + PJV2012

PML7789 + PJV2012 is a drug combination identifier that does not correspond to any known clinical or preclinical assets in public pharmaceutical databases. These codes appear to be typographical variations of the Novartis development codes **PML789** (ganaplacide, also known as KAF156) and **PJV201** (cipargamin, also known as KAE609). PML789 is an experimental antimalarial that inhibits the *Plasmodium falciparum* phosphatidylinositol 4-kinase (PI4K) enzyme, which is essential for the parasite's life cycle in both the liver and blood stages. PJV201 is a spiroindolone antimalarial that targets the *P. falciparum* P-type ATPase 4 (PfATP4), an ion pump required for maintaining sodium homeostasis within the parasite. While Novartis has investigated various combinations within its antimalarial portfolio, the specific codes 'PML7789' and 'PJV2012' are not recognized identifiers for these or any other known therapeutic agents.